Suzhou-based bio-pharmaceutical company TOT Biopharm has raised US$102 million series B round led by Chinese local asset management 99Fund, according to the company’s announcement.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?